Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Kennedy EM, Farkaly T, Grzesik P, Lee J, Denslow A, Hewett J, Bryant J, Behara P, Goshert C, Wambua D, De Almeida A, Jacques J, Deavall D, Rottman JB, Glorioso JC, Finer MH, Haines BB, Quéva C, Lerner L.
Kennedy EM, et al. Among authors: deavall d.
Mol Ther Oncolytics. 2020 Aug 8;18:476-490. doi: 10.1016/j.omto.2020.08.004. eCollection 2020 Sep 25.
Mol Ther Oncolytics. 2020.
PMID: 32953982
Free PMC article.